The ACE inhibitor ramipril was used as a reference agent. Patients and Methods: A group of 104 adult patients with arterial hypertension and respiratory disorders took part in a double-blind ...

Luckily, you have patented your new idea. And so, you take the patent violator to court and win. One would assume that such a victory would put an end to the theft. But that’s not how the legal ...

March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...

The U.S. patent system feels to me an awful lot like the Titanic right now, and it feels like we’re fast approaching an iceberg with disaster imminent. The Trump Administration is making major ...

Every year, the UK spends an estimated £2.6billion on generic drugs - medicines that are taken by millions of NHS patients ...

It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022. The court ...

A nearly exponential surge in patent activity related to space exploration, particularly over the past decade and a half, has captured a snapshot of these developments. Along with these ...

Merck has been tweaking Keytruda to make it easier to use—and to protect billions of dollars in revenue the company could lose after U.S. patent protection runs out in 2028 and rivals can begin ...

Despite their established effectiveness, uptake of the WHO best buys for tackling non-communicable diseases (NCDs) has been ...

For five weeks, employees at NIH technology transfer offices have been barred from filing new patent applications and been restricted from licensing existing ones, according to emails obtained by ...

Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of infringing were invalid. The companies have secured a victory in a round in their ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...